We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+11.72%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.39B
AUM Growth
-$174M
(-4.9%)
Cap. Flow
+$54.8M
Cap. Flow
% of AUM
1.62%
Top 10 Holdings %
Top 10 Hldgs %
46.4%
Holding
115
New
19
Increased
20
Reduced
20
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$127M |
| 2 |
ACLX
Arcellx
ACLX
|
+$37.7M |
| 3 |
Sanofi
SNY
|
+$37.4M |
| 4 |
Iovance Biotherapeutics
IOVA
|
+$37M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$32M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$109M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$50.4M |
| 3 |
VRNA
Verona Pharma
VRNA
|
+$46.4M |
| 4 |
ALBO
Albireo Pharma Inc
ALBO
|
+$38M |
| 5 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
+$31.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.7% |
| 2 | Miscellaneous | 0.23% |
| 3 | Financials | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Natera
NTRA
$50.6B
| $39.3M | 1.16% |
707,214
+577,214
| +444% | +$27.7M |
|
27
Acrivon Therapeutics
ACRV
$78.4M
| $38.2M | 1.13% |
3,007,858
| – | – |
|
|
APLS
28
DELISTED
Apellis Pharmaceuticals
APLS
| $36.6M | 1.08% |
+555,344
| New | +$32M |
|
29
MeiraGTx Holdings
MGTX
$1.23B
| $36M | 1.06% |
6,963,277
| – | – |
|
|
30
Sarepta Therapeutics
SRPT
$2.19B
| $36M | 1.06% |
260,858
-388,392
| -60% | -$50.4M |
|
|
BLU
31
DELISTED
BELLUS Health Inc.
BLU
| $35.7M | 1.05% |
4,952,538
-3,938,489
| -44% | -$30.5M |
|
|
CBAY
32
DELISTED
Cymabay Therapeutics
CBAY
| $34M | 1% |
3,903,255
+3,194,262
| +451% | +$25.6M |
|
33
Verrica Pharmaceuticals
VRCA
$78.7M
| $32.8M | 0.97% |
503,898
| – | – |
|
34
Relay Therapeutics
RLAY
$4.16B
| $32M | 0.94% |
1,943,097
| – | – |
|
35
Establishment Labs
ESTA
$2.13B
| $31.7M | 0.94% |
467,857
-30,000
| -6% | -$2.06M |
|
36
BridgeBio Pharma
BBIO
$13.4B
| $31.6M | 0.93% |
1,907,033
+210,000
| +12% | +$2.45M |
|
37
Zymeworks
ZYME
$1.86B
| $30.5M | 0.9% |
3,378,498
-1,132,777
| -25% | -$9.88M |
|
|
ATXS
38
DELISTED
Astria Therapeutics
ATXS
| $29.1M | 0.86% |
2,189,462
| – | – |
|
39
Nautilus Biotechnolgy
NAUT
$113M
| $25.2M | 0.75% |
9,111,151
| – | – |
|
40
Cogent Biosciences
COGT
$5.68B
| $24.6M | 0.73% |
2,282,324
-925,117
| -29% | -$11.8M |
|
41
Immatics
IMTX
$1.31B
| $24.1M | 0.71% |
3,491,500
| – | – |
|
42
Protagonist Therapeutics
PTGX
$9.28B
| $22.2M | 0.66% |
+965,152
| New | +$16.2M |
|
43
Outset Medical
OM
$59M
| $20M | 0.59% |
72,628
| – | – |
|
44
Immunovant
IMVT
$7.57B
| $20M | 0.59% |
1,291,858
+1,141,858
| +761% | +$19.8M |
|
|
AKRO
45
DELISTED
Akero Therapeutics
AKRO
| $20M | 0.59% |
523,525
+173,000
| +49% | +$7.71M |
|
46
Roivant Sciences
ROIV
$28.5B
| $19.9M | 0.59% |
2,692,136
+710,566
| +36% | +$5.85M |
|
|
LYRA
47
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $18.4M | 0.54% |
182,935
| – | – |
|
48
Solid Biosciences
SLDB
$897M
| $16.6M | 0.49% |
3,495,933
| – | – |
|
49
Tarsus Pharmaceuticals
TARS
$3.66B
| $16.3M | 0.48% |
1,296,416
| – | – |
|
|
TERN
50
DELISTED
Terns Pharmaceuticals
TERN
| $16M | 0.47% |
+1,350,000
| New | +$12.9M |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q1 2023 Portfolio in Review
As of Q1 2023, Perceptive Advisors held 115 positions worth $3.39B, down 4.9% from $3.56B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Perceptive Advisors's Q1 2023 filing shows 19 new, 20 increased, 20 reduced and 16 closed positions. Its largest new stake was Reata Pharmaceuticals, Inc. Class A Common Stock: 2,169,276 shares worth $197M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $109M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.
- Perceptive Advisors's largest Q1 2023 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 2,169,276 shares worth $197M.
- Perceptive Advisors added most to Arcellx in Q1 2023, an estimated $37.7M increase.
- Perceptive Advisors's biggest Q1 2023 reduction was Sarepta Therapeutics, cutting an estimated $50.4M.
- Perceptive Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $109M.
- Perceptive Advisors's ten largest holdings make up 46% of its $3.39B portfolio in Q1 2023.
- Perceptive Advisors opened 19 new positions and closed 16 in Q1 2023.
- Perceptive Advisors's portfolio value fell 4.9% quarter-over-quarter to $3.39B.
Based on Perceptive Advisors's 13F filing for Q1 2023, filed 15 May 2023.